News | February 25, 2026
UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
If approved, DTX401 would be the first treatment to address the disease at its root cause
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Under the deal, Quiver will receive an undisclosed advance payment and research support
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Subscribe To Our Newsletter & Stay Updated
